Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Long-term safety and efficacy of tagraxofusp in BPDCN: results from a subgroup analysis

Naveen Pemmaraju • 1 Jun 2025
ASCO 2025
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares insights into the long-term safety and efficacy of tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This agent has shown promising outcomes, with certain subgroups of patients benefiting from the drug, and no new safety signals observed. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naveen Pemmaraju

The value and interactive format of the MPN Workshop of the Carolinas 6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju et al. • 22 Aug 2025
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN 2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more 1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV 2:17
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
Naveen Pemmaraju • 31 May 2025

Related Videos

Refining the diagnosis and classification of CMML 6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
Improving the diagnosis of amyloidosis: advice that can be applied in practice 2:48
Improving the diagnosis of amyloidosis: advice that can be applied in practice
Gareth Morgan • 18 Sep 2025
Ongoing research in gray zone lymphoma 1:07
Ongoing research in gray zone lymphoma
Kieron Dunleavy • 4 Sep 2025
Insights into gray zone lymphoma: a rare subtype of NHL 1:14
Insights into gray zone lymphoma: a rare subtype of NHL
Kieron Dunleavy • 4 Sep 2025
The content of VJHemOnc is intended for healthcare professionals